359 related articles for article (PubMed ID: 34255338)
21. [Summary of the ESC position paper on cancer treatment and cardiovascular toxicity].
Hoog J; Achenbach S
Herz; 2016 Dec; 41(8):684-689. PubMed ID: 27830273
[TBL] [Abstract][Full Text] [Related]
22. Multimodality Imaging for Cardiotoxicity: State of the Art and Future Perspectives.
Artico J; Abiodun A; Shiwani H; Kurdi H; Chen D; Tyebally S; Moon JC; Westwood M; Manisty CH
J Cardiovasc Pharmacol; 2022 Oct; 80(4):547-561. PubMed ID: 35522143
[TBL] [Abstract][Full Text] [Related]
23. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.
Butel-Simoes LE; Haw TJ; Williams T; Sritharan S; Gadre P; Herrmann SM; Herrmann J; Ngo DTM; Sverdlov AL
Hypertension; 2023 Apr; 80(4):685-710. PubMed ID: 36756872
[TBL] [Abstract][Full Text] [Related]
24. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.
Berardi R; Caramanti M; Savini A; Chiorrini S; Pierantoni C; Onofri A; Ballatore Z; De Lisa M; Mazzanti P; Cascinu S
Crit Rev Oncol Hematol; 2013 Oct; 88(1):75-86. PubMed ID: 23522920
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Toxicities in Pediatric Cancer Survivors.
Ryan TD; Nagarajan R; Godown J
Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793
[TBL] [Abstract][Full Text] [Related]
26. [Management of Cancer Patients with Cardiovascular Complications - Onco-Cardiology].
Mukai M
Gan To Kagaku Ryoho; 2016 Aug; 43(8):940-4. PubMed ID: 27539035
[TBL] [Abstract][Full Text] [Related]
27. Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment.
Oikonomou E; Anastasiou Μ; Siasos G; Androulakis E; Psyrri A; Toutouzas K; Tousoulis D
Curr Pharm Des; 2018; 24(37):4424-4435. PubMed ID: 30636595
[TBL] [Abstract][Full Text] [Related]
28. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies.
Adão R; de Keulenaer G; Leite-Moreira A; Brás-Silva C
Rev Port Cardiol; 2013 May; 32(5):395-409. PubMed ID: 23623503
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
Pantazi D; Tselepis AD
Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
[TBL] [Abstract][Full Text] [Related]
30. Arrhythmic Complications Associated with Cancer Therapies.
Pothineni NVK; Van Besien H; Fradley MG
Heart Fail Clin; 2022 Jul; 18(3):375-383. PubMed ID: 35718413
[TBL] [Abstract][Full Text] [Related]
31. The Role of Cardio-Oncology in the Interprofessional Care of Adult Patients Receiving Cancer Therapy.
Pituskin E; Paterson I; Cox-Kennett N; Rothe D; Perri M; Becher H
Semin Oncol Nurs; 2017 Nov; 33(4):384-392. PubMed ID: 28941563
[TBL] [Abstract][Full Text] [Related]
32. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
[TBL] [Abstract][Full Text] [Related]
33. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.
Beyer AM; Bonini MG; Moslehi J
Am J Physiol Heart Circ Physiol; 2019 Jul; 317(1):H164-H167. PubMed ID: 31172808
[TBL] [Abstract][Full Text] [Related]
34. Antineoplastic drugs inducing cardiac and vascular toxicity - An update.
Barachini S; Ghelardoni S; Varga ZV; Mehanna RA; Montt-Guevara MM; Ferdinandy P; Madonna R
Vascul Pharmacol; 2023 Dec; 153():107223. PubMed ID: 37678516
[TBL] [Abstract][Full Text] [Related]
35. Long-term arterial complications of chemotherapy in patients with cancer.
Svilaas T; Lefrandt JD; Gietema JA; Kamphuisen PW
Thromb Res; 2016 Apr; 140 Suppl 1():S109-18. PubMed ID: 27067963
[TBL] [Abstract][Full Text] [Related]
36. Emergence of cardio-oncology.
Nebigil CG; Désaubry L
Ann Pharm Fr; 2018 Nov; 76(6):504-506. PubMed ID: 30075937
[TBL] [Abstract][Full Text] [Related]
37. Cancer treatment-related cardiovascular disease: Current status and future research priorities.
Nonaka M; Hosoda H; Uezono Y
Biochem Pharmacol; 2021 Aug; 190():114599. PubMed ID: 33989656
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.
Raschi E; De Ponti F
Intern Emerg Med; 2012 Apr; 7(2):113-31. PubMed ID: 22161318
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment.
Yegya-Raman N; Berlin E; Feigenberg SJ; Ky B; Sun L
Curr Oncol Rep; 2023 May; 25(5):433-444. PubMed ID: 36811807
[TBL] [Abstract][Full Text] [Related]
40. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
